Literature DB >> 17568659

Fibrinogen Aalpha-Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolism.

Grégoire Le Gal1, Bénédicte Delahousse, Karine Lacut, Vincent Malaviolle, Sandra Regina, Marie-Thérèse Blouch, Francis Couturaud, Dominique Mottier, Emmanuel Oger, Yves Gruel.   

Abstract

INTRODUCTION: Fibrinogen Aalpha-Thr312Ala and Factor XIII Val34Leu polymorphisms have been shown to modify fibrin clot structure and function. However, clinical studies have yielded conflicting results on their possible association with venous thromboembolism (VTE).
METHODS: We studied the association between these two polymorphisms and VTE in a hospital-based case-control study. We also assessed whether an independent or interactive association exists between Aalpha-fibrinogen Thr312Ala and FXIII Val34Leu polymorphisms and VTE. Fibrinogen Aalpha-Thr312Ala and FXIII Val34Leu polymorphisms were determined after PCR and restriction endonuclease digestion in 286 patients with idiopathic VTE and 286 age- and gender-matched controls. Results were analysed using a conditional logistic regression model for matched series.
RESULTS: The Fg-Aalpha 312Ala allele was associated with higher risk of VTE (OR 1.5; 95% CI: 1.1 to 2.2, p=0.01) while the FXIII 34Leu allele appeared protective (OR 0.7; 95% CI: 0.6 to 0.9, p=0.02). Both alleles demonstrated an independent association with idiopathic VTE after adjustment for Factor V Leiden and G20210A prothrombin polymorphisms. There was no interaction between the fibrinogen Aalpha-Thr312Ala and FXIII Val34Leu polymorphisms for the risk of VTE.
CONCLUSION: In this case-control study, the fibrinogen Fg-Aalpha 312Ala allele was associated with an increased risk of VTE. The FXIII 34Leu allele was also significantly associated with a lower risk of VTE without any interaction between the two polymorphisms studied.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17568659     DOI: 10.1016/j.thromres.2007.05.003

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Susceptibility to chronic thromboembolic pulmonary hypertension may be conferred by miR-759 via its targeted interaction with polymorphic fibrinogen alpha gene.

Authors:  Zhiyong Chen; Toshiaki Nakajima; Nobuhiro Tanabe; Kunihiko Hinohara; Seiichiro Sakao; Yasunori Kasahara; Koichiro Tatsumi; Yoshinori Inoue; Akinori Kimura
Journal:  Hum Genet       Date:  2010-07-31       Impact factor: 4.132

2.  A genetic association study of D-dimer levels with 50K SNPs from a candidate gene chip in four ethnic groups.

Authors:  Lu-Chen Weng; Weihong Tang; Stephen S Rich; Nicholas L Smith; Susan Redline; Christopher J O'Donnell; Saonli Basu; Alexander P Reiner; Joseph A Delaney; Russell P Tracy; Cameron D Palmer; Taylor Young; Qiong Yang; Aaron R Folsom; Mary Cushman
Journal:  Thromb Res       Date:  2014-05-20       Impact factor: 3.944

3.  Association of fibrinogen and plasmin inhibitor, but not coagulation factor XIII gene polymorphisms with coronary artery disease.

Authors:  Ana Bronić; Goran Ferenčak; Robert Bernat; Jasna Leniček-Krleža; Jerka Dumić; Sanja Dabelić
Journal:  J Med Biochem       Date:  2021-03-12       Impact factor: 3.402

4.  Association of vWA and TPOX polymorphisms with venous thrombosis in Mexican mestizos.

Authors:  Marco Antonio Meraz-Ríos; Abraham Majluf-Cruz; Carla Santana; Gino Noris; Rafael Camacho-Mejorado; Leonor C Acosta-Saavedra; Emma S Calderón-Aranda; Jesús Hernández-Juárez; Jonathan J Magaña; Rocío Gómez
Journal:  Biomed Res Int       Date:  2014-08-31       Impact factor: 3.411

Review 5.  Extension of the Human Fibrinogen Database with Detailed Clinical Information-The αC-Connector Segment.

Authors:  Zofie Sovova; Klara Pecankova; Pavel Majek; Jiri Suttnar
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.